报价延迟最少15分钟:2026/03/02 20:00 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.59 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-14.70/-2.51
|
|
企业价值
342.28M
|
| 资产负债 |
|
每股账面净值
-15.97
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
145.24M
|
|
每股收益
7.95
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor). |
